ImpediMed

ImpediMed Financial Debt Ratio

The Financial Debt Ratio of ImpediMed (IPD.AX) as of Nov 12, 2026 is 47.88 %. In the previous year, Financial Debt Ratio was 34.78 % — a change of 37.65% (higher).

Financial Debt Ratio

47.88 %

YoY

37.65%

Last updated:

Financial Debt Ratio of ImpediMed is 2026 47.88 % . Financial Debt Ratio of ImpediMed was 2025 34.78 % . It decreases by 37.65% higher compared to the previous year.

The ImpediMed Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2019
3.86 AUD
Jan 1, 2020
2.63 AUD
Jan 1, 2021
1.39 AUD
Jan 1, 2022
0.29 AUD
Jan 1, 2023
2.11 AUD
Jan 1, 2024
2.43 AUD
Jan 1, 2025
34.78 AUD
Jan 1, 2026
47.88 AUD
The ImpediMed Financial Debt Ratio history
YEARFinancial Debt RatioYoY
47.88 %+37.65%
34.78 %+1,329.89%
2.43 %+15.56%
2.11 %+626.89%
0.29 %-79.10%
1.39 %-47.40%
2.63 %-31.71%
3.86 %+597.13%
0.55 %+513.81%
0.09 %+11.84%
0.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Financial Debt Ratio of ImpediMed is 47.88 % in 2026.

Financial Debt Ratio of ImpediMed changed from 34.78 % to 47.88 %, representing a 37.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio ImpediMed since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's ImpediMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ImpediMed

All Key Metrics — ImpediMed